Close | |
Figure 3:(a) Mean change in visual acuity letter score over time for the full cohort over a period of 1 year, the mean visual acuity letter score improved by about 13 with aflibercept, by 10 with bevacizumab, and by 11 with ranibizumab. (b) When the initial visual acuity letter score was 78–69 (equivalent to approximately 20/32–20/40), the mean improvement was about 8.0 with no significant difference between aflibercept, bevacizumab, and ranibizumab. (c) When the initial letter score was < 69 (approximately 20/50 or worse), the mean improvement was about 19 with aflibercept, 12 with bevacizumab, and 14 with ranibizumab. (d) Mean change in optical coherence tomography central subfield thickness over time the overall decrease in central subfield thickness over 1 year was 101 um for bevacizumab, 147 um for ranibizumab, and 169 um for aflibercept (courtesy of Diabetic Retinopathy Clinical Research Network) |
|